332 related articles for article (PubMed ID: 19062090)
21. The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.
Piazza RG; Magistroni V; Franceschino A; Andreoni F; Tornaghi L; Colnaghi F; Corneo G; Pogliani EM; Gambacorti-Passerini C
Blood Cells Mol Dis; 2006; 37(2):111-5. PubMed ID: 16908206
[TBL] [Abstract][Full Text] [Related]
22. Has the time come for induction and maintenance imatinib therapy in chronic myeloid leukemia?
Faber E
Leuk Res; 2009 May; 33(5):605-6. PubMed ID: 19062091
[TBL] [Abstract][Full Text] [Related]
23. Complete molecular remission in chronic myelogenous leukemia after imatinib therapy.
Barbany G; Höglund M; Simonsson B;
N Engl J Med; 2002 Aug; 347(7):539-40. PubMed ID: 12181416
[No Abstract] [Full Text] [Related]
24. Chronic myelogenous leukaemia (CML): an update.
Kumar L
Natl Med J India; 2006; 19(5):255-63. PubMed ID: 17203680
[TBL] [Abstract][Full Text] [Related]
25. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
Cortes JE; Talpaz M; O'Brien S; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Rios MB; Shan J; Kantarjian HM
Cancer; 2006 Mar; 106(6):1306-15. PubMed ID: 16463391
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
Branford S; Hughes T; Milner A; Koelmeyer R; Schwarer A; Arthur C; Filshie R; Moreton S; Lynch K; Taylor K
Cancer; 2007 Aug; 110(4):801-8. PubMed ID: 17607681
[TBL] [Abstract][Full Text] [Related]
27. Mean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukemia patients treated with imatinib?
Song MK; Chung JS; Seol YM; Kim SG; Shin HJ; Choi YJ; Cho GJ
Leuk Res; 2009 Nov; 33(11):1459-62. PubMed ID: 19446878
[TBL] [Abstract][Full Text] [Related]
28. [Therapy of chronic myelogenous leukemia in 2004].
Hochhaus A; Berger U; Hehlmann R
Dtsch Med Wochenschr; 2004 Oct; 129(40):2122-7. PubMed ID: 15455305
[TBL] [Abstract][Full Text] [Related]
29. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors.
Angstreich GR; Matsui W; Huff CA; Vala MS; Barber J; Hawkins AL; Griffin CA; Smith BD; Jones RJ
Br J Haematol; 2005 Aug; 130(3):373-81. PubMed ID: 16042686
[TBL] [Abstract][Full Text] [Related]
30. Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.
Malagola M; Breccia M; Skert C; Cancelli V; Soverini S; Iacobucci I; Cattina F; Liberati AM; Tiribelli M; Annunziata M; Trabacchi E; De Vivo A; Castagnetti F; Martinelli G; Fogli M; Stagno F; Pica G; Iurlo A; Pregno P; Abruzzese E; Pardini S; Bocchia M; Russo S; Pierri I; Lunghi M; Barulli S; Merante S; Mandelli F; Alimena G; Rosti G; Baccarani M; Russo D
Am J Hematol; 2014 Feb; 89(2):119-24. PubMed ID: 24122886
[TBL] [Abstract][Full Text] [Related]
31. [Molecular relapse of chronic myeloid leukemia after discontinuation of imatinib mesylate for maintaining complete molecular response for more than 2 years].
Kiguchi T; Tauchi T; Ohyashiki K
Rinsho Ketsueki; 2009 Jan; 50(1):52-4. PubMed ID: 19225231
[TBL] [Abstract][Full Text] [Related]
32. Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission.
Pavlu J; Andreasson C; Chuah C; Kaeda J; Goldman JM; Apperley JF; Marin D
Br J Haematol; 2007 Jun; 137(5):423-8. PubMed ID: 17428238
[TBL] [Abstract][Full Text] [Related]
33. Autologous stem cells collected after debulking by high dose chemotherapy in late phase chronic myeloid leukemia may improve Imatinib efficacy.
Kalayoglu-Besisik S; Ozturk GB; Caliskan Y; Nalcaci M; Gurses N; Cin N; Ozbek U; Sargin D
Transfus Apher Sci; 2007 Feb; 36(1):91-4. PubMed ID: 17222585
[TBL] [Abstract][Full Text] [Related]
34. Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow up.
Hess G; Meyer RG; Schuch B; Bechthold K; El-Kholy I; Huber C
Am J Hematol; 2008 Mar; 83(3):178-84. PubMed ID: 17876770
[TBL] [Abstract][Full Text] [Related]
35. Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature.
Guastafierro S; Falcone U; Celentano M; Coppola M; Ferrara MG; Sica A
Leuk Res; 2009 Aug; 33(8):1079-81. PubMed ID: 19167064
[TBL] [Abstract][Full Text] [Related]
36. The role of interferon-alpha in the treatment of chronic myeloid leukemia.
Kujawski LA; Talpaz M
Cytokine Growth Factor Rev; 2007; 18(5-6):459-71. PubMed ID: 17703986
[TBL] [Abstract][Full Text] [Related]
37. Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia.
Ghanima W; Kahrs J; Dahl TG; Tjonnfjord GE
Eur J Haematol; 2004 Jun; 72(6):441-3. PubMed ID: 15128424
[TBL] [Abstract][Full Text] [Related]
38. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial.
Bocchia M; Gentili S; Abruzzese E; Fanelli A; Iuliano F; Tabilio A; Amabile M; Forconi F; Gozzetti A; Raspadori D; Amadori S; Lauria F
Lancet; 2005 Feb 19-25; 365(9460):657-62. PubMed ID: 15721470
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics and hematologic responses to Imatinib in patients with chronic phase myeloid leukemia (CML) at Cipto Mangunkusumo Hospital.
Reksodiputro AH; Syafei S; Prayogo N; Karsono B; Rinaldi I; Rajabto W; Mulansari NA
Acta Med Indones; 2010 Jan; 42(1):2-5. PubMed ID: 20305324
[TBL] [Abstract][Full Text] [Related]
40. Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developing country.
Aziz Z; Iqbal J; Akram M; Saeed S
Cancer; 2007 Mar; 109(6):1138-45. PubMed ID: 17315159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
